These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Dementia: what the primary care physician must know about it]. Wettstein A Praxis (Bern 1994); 2001 Oct; 90(40):1725-30. PubMed ID: 11680211 [TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies. Gustavsson A; Van Der Putt R; Jönsson L; McShane R Int J Geriatr Psychiatry; 2009 Oct; 24(10):1072-8. PubMed ID: 19639600 [TBL] [Abstract][Full Text] [Related]
8. [Cost-effectiveness of galantamine in a german context]. Happich M; Schweikert B; Mühlbacher A Psychiatr Prax; 2005 Apr; 32(3):142-50. PubMed ID: 15818530 [TBL] [Abstract][Full Text] [Related]
9. [Dementias: mostly clinico-neuropsychological or mostly psychometric diagnosis?]. Spinnler H Ann Ist Super Sanita; 2005; 41(1):75-80. PubMed ID: 16037654 [TBL] [Abstract][Full Text] [Related]
11. [Converging opinions of a multidisciplinary group of French experts on diagnostic and therapeutic modalities for Alzheimer type dementia]. Petit H; Albarède JL; Bakchine S; Boulliat J; Cogneau J; Darcourt G; Dubois B; Forette F; Franco A; Héres J; Hinault P; Laurent B; Léger JM; Marin La Meslée R; Montagne B; Poncet M; Robert P; Sorbé G; Touchon J; Velas B; Vetel JM Rev Neurol (Paris); 2000 May; 156(5):542-52. PubMed ID: 10844378 [No Abstract] [Full Text] [Related]
12. [Dementias. Diagnosis and therapy are overwhelmingly the responsibility of the family physician]. Kurz A; Speer W MMW Fortschr Med; 2001 May; 143 Suppl 2():27-32. PubMed ID: 11434253 [TBL] [Abstract][Full Text] [Related]
13. Cholinesterase inhibitors in the treatment of Alzheimer's disease and related dementias. Masterman D Clin Geriatr Med; 2004 Feb; 20(1):59-68. PubMed ID: 15062487 [No Abstract] [Full Text] [Related]
14. Galantamine improves gait performance in patients with Alzheimer's disease. Assal F; Allali G; Kressig RW; Herrmann FR; Beauchet O J Am Geriatr Soc; 2008 May; 56(5):946-7. PubMed ID: 18454755 [No Abstract] [Full Text] [Related]
16. Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Winblad B; Hill S; Beermann B; Post SG; Wimo A Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():39-45. PubMed ID: 9305515 [No Abstract] [Full Text] [Related]
17. [Cost control in Alzheimer therapy. "Second class patient"]. MMW Fortschr Med; 2002 Dec; 144(50):67. PubMed ID: 14610878 [No Abstract] [Full Text] [Related]
18. Experts disagree over NICE's approach for assessing drugs. Hoey R Lancet; 2007 Aug; 370(9588):643-4. PubMed ID: 17726791 [No Abstract] [Full Text] [Related]
19. Counting costs. Patients will suffer from limits on Alzheimer's drugs. Page S Nurs Stand; 2005 May 25-31; 19(37):24-5. PubMed ID: 15938410 [TBL] [Abstract][Full Text] [Related]
20. [Therapy in Alzheimer disease]. Kovács T Orv Hetil; 2004 Apr; 145(17):925-8. PubMed ID: 15170971 [No Abstract] [Full Text] [Related] [Next] [New Search]